Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced that its Benidipine Hydrochloride, used for treating primary hypertension and angina pectoris, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step for the company in enhancing its product offerings and could potentially strengthen its position in the pharmaceutical market, benefiting both shareholders and potential investors.
More about SSY Group
SSY Group Limited is a company involved in the pharmaceutical industry, focusing on the development and production of pharmaceutical products. Its primary products include medications for treating hypertension and angina pectoris, with a specific market focus on the Chinese healthcare sector.
YTD Price Performance: 1.86%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.3B
For an in-depth examination of 2005 stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- 3 Penny Stocks to Watch Now, 1/7/25
- Super Micro Computer Stock Jumps 15% on Liquid Cooling Tech Prospects
- Meta Appoints Trump Ally Dana White to Board
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
